Difference between revisions of "Team:Shenzhen SFLS/Investigation"

 
(16 intermediate revisions by the same user not shown)
Line 6: Line 6:
 
</div>
 
</div>
 
<div id="content2">
 
<div id="content2">
 +
<p id="invest">
 +
There are two pages
 +
</p>
 +
<p id="page">
 +
<a href="https://2015.igem.org/Team:Shenzhen_SFLS/Investigation_2">Next</a>
 +
</p>
 +
<p id="invest">　Investigation on cancer and cancer therapy
 +
Written by Yilin Wang, survey conducted by Yilin Wang, popularization articles written by Fanghui He
 +
</br>　As we formed our project in the inspiration of cancer threrapy, we felt that further investigation on cancer and cancer therapy will help us improve our project. We developed our investigation in three stages.
 +
</br>　In the first stage, we collected some data on the Internet and conducted a survey about public cognition on cancer and cancer therapy.
 +
</br>　In the second stage, we visited some hospitals and deepened our investigation by doing survey focusing on real clinical application of cancer therapies and interviewed Doctor Xianming Li in Shenzhen Renmin hospital in addition.
 +
</br>　In the third stage, we improved our detailed application blueprints according to the results of hospital survey and the aim of solving the existing problems in applying ADCs.
 +
</br>　Additionally, we documented several articles on our We-chat Public Platform, aiming at popularizing the knowledge we gained about cancer and cancer therapy.
 +
</br></br>About cancer
 +
</br>------Stage 1
 +
</br>　Cancer has been one of the most formidable enemies human faces. 8 million deaths were related to cancer in 2012 worldwide, together with approximately 14 million new cases diagnosed.  Although China isn't the most affected country by cancer, according to the world incidence rates, its large population and developing public medical services still lead to considerable mortality. In China, cancer accounted for 23.92% of overall deaths in 2010.  And the incidence rate is still growing.
 +
</p>
 
<img src="https://static.igem.org/mediawiki/2015/1/16/Investigation_fig1.jpeg" />
 
<img src="https://static.igem.org/mediawiki/2015/1/16/Investigation_fig1.jpeg" />
 
<p id="invest">
 
<p id="invest">
−
Fig.1</br> The 10 leading causes of death worldwide in 2011. COPD, chronic obstructive pulmonary disease.
+
Fig.1 The 10 leading causes of death worldwide in 2011. COPD, chronic obstructive pulmonary disease.
−
</br>Generations of scientists devoted their efforts to fighting with cancer. </br>However, besides continuously developing treatment thechnology,</br> people’s well cognition on the disease is also required for fighting against the disease.
+
</br>　Generations of scientists devoted their efforts to fighting with cancer. </br>However, besides continuously developing treatment thechnology, people’s well cognition on the disease is also required for fighting against the disease.
−
</br>To observe public cogniton on cancer and cancer therapy, </br>we documented our survey on our Wechat Public Platform, </br>an online public platform, and received feedback of an amount of over 600 . The results analyzed are printed below.
+
</br>　To observe public cogniton on cancer and cancer therapy, </br>we documented our survey on our Wechat Public Platform, </br>an online public platform, and received feedback of an amount of over 600 . The results analyzed are printed below.
 
</p>
 
</p>
 
<img src="https://static.igem.org/mediawiki/2015/9/97/Investigation_fig2.jpeg" />
 
<img src="https://static.igem.org/mediawiki/2015/9/97/Investigation_fig2.jpeg" />
 
<img src="https://static.igem.org/mediawiki/2015/9/9b/Investigation_fig3.jpeg" />
 
<img src="https://static.igem.org/mediawiki/2015/9/9b/Investigation_fig3.jpeg" />
−
<p id="invest">Fig. 2 & Fig.3  
+
<p id="invest">Fig. 2 & Fig.3 Our survey conducted among public  
−
</br>Our survey conducted among public  
+
</br>　Via: We-chat Public Platform
−
</br>Via: We-chat Public Platform
+
 
</p>
 
</p>
 
<img src="https://static.igem.org/mediawiki/2015/8/8b/Investigation_fig4.jpeg" />
 
<img src="https://static.igem.org/mediawiki/2015/8/8b/Investigation_fig4.jpeg" />
 
<p id="invest">
 
<p id="invest">
−
Fig. 4  
+
Fig. 4 　The feedback of public cognition on cancer
−
</br>The feedback of public cognition on cancer
+
 
</p>
 
</p>
 
<p id="invest">
 
<p id="invest">
−
<img src="https://static.igem.org/mediawiki/2015/2/2c/Investigation_fig5.jpeg">
+
<img src="https://static.igem.org/mediawiki/2015/2/2c/Investigation_fig5.jpeg"/>
−
Fig.5
+
Fig.5 The feedback of public cognition on cancer therapy
−
</br>The feedback of public cognition on cancer therapy
+
</br>　As the results shown, when asked about cancer, most people remain knowing "not so much" or "almost nothing at all". And only 19% of the people surveyed know about technologies beside the three main treatment methods(Chemotherapy, Radiotherapy, Surgical Treatment), such as targeted therapy and immunological therapy which may perform more promisingly in future application.  
−
</br> As the results shown, when asked about cancer, most people remain knowing "not so much" or "almost nothing at all". And only 19% of the people surveyed know about technologies beside the three main treatment methods(Chemotherapy, Radiotherapy, Surgical Treatment), such as targeted therapy and immunological therapy which may perform more promisingly in future application.  
+
</br>P.S. Therefore, we developed Stage 3, introducing the frontier technologies in cancer treatment field to popularize knowledge of cancer and cancer to the public.
−
</br></br>P.S. Therefore, we developed Stage 3, introducing the frontier technologies in cancer treatment field to popularize knowledge of cancer and cancer to the public.
+
 
</br></br>Clinical Application of immunological cancer therapies
 
</br></br>Clinical Application of immunological cancer therapies
 
</br>------Stage 2
 
</br>------Stage 2
−
</br> Aiming at looking into the application landscape of cancer therapies, especially the immunological therapies which is related closely to our project, we conduct a survey in two hospitals.
+
</br>　Aiming at looking into the application landscape of cancer therapies, especially the immunological therapies which is related closely to our project, we conduct a survey in two hospitals.
−
</br> By conducting the survey, we collected information about the application frequency of different therapies in treating patients in different stages.  
+
</br>　By conducting the survey, we collected information about the application frequency of different therapies in treating patients in different stages.  
 
</p>
 
</p>
 
<p id="invest">
 
<p id="invest">
−
<img src="https://static.igem.org/mediawiki/2015/b/bf/Investigation_fig6.jpeg" />
+
There are two pages
−
Fig.6
+
−
</br>Application Frequency of different therapiesin different stages in 2014
+
−
</br>In Shenzhen Renmin Hospital
+
 
</p>
 
</p>
−
<p id="invest">
+
<p id="page">
−
<img src="">
+
<a href="https://2015.igem.org/Team:Shenzhen_SFLS/Investigation_2">Next</a>
−
Fig.7 Application Frequency of different therapies in different stages  in 2014
+
−
</br>In Shenzhen Second Renmin Hospital
+
−
</br>  As shown in Fig.4 and Fig.5, Surgical treatment and Chemothrapy are most frequently used methods in cancer therapy. The former is applied in early stage primarily and the latter is primarily applied in Middle Stage and Final Stage, while immunological treatment methods, which we take Monoclonal Antibody Drug as an example of, are mostly used as helpers to the two therapies mentioned above.
+
−
</br></br>  We interviewed Doctor Xianming Li who is the Chief of Tumor Radiotherapy Department in Shenzhen Renmin Hospital. Together, we discussed about the major factors which decide the current status of the application of immunological therapies and the view on cancer therapy development.
+
−
</br>  Doctor Li suggested that the immunological therapies currently developed perform well in accuracy. But most of them kill tumor cells less directly compared with surgical treatment and sometimes less aggressive compared with chemotherapy. As a result, immunological methods are mostly used before or after surgical treatments or chemotherapy to enhance the effect.
+
−
</br>  Talking about ADCs, he also shared with us the experience of applying ADCs like drugs to treating a kind of as clinical trails. The treatment turned out to be a failure however due to the uncontrolled high toxicity of the durgs conjugated. Accordingly, Doctor Li pointed out that how to control the toxicity of drugs during drug delivering process and how to reduce undesirable immune system reponses are the two cure problems remained to be solved.
+
−
</br>When asked about his view on the future prospects of biological cancer therapy, Doctor Li used "absolutely promising" to express his opinion and he also gave suggestions on us choosing effector molecule in our project.
+
−
</p>
+
−
<p id="invest">
+
−
<img src="https://static.igem.org/mediawiki/2015/1/17/Investigation_fig8.jpg">
+
−
Fig.8 Doctor Xianming Li--- the Chief of Tumor Radiotherapy Department in Shenzhen Renmin Hospital
+
 
</p>
 
</p>
−
<p id"invest">
 
−
<img src"">
 
 
</div>
 
</div>
 
</div>
 
</div>

Latest revision as of 13:36, 18 September 2015

;

There are two pages

Next

　Investigation on cancer and cancer therapy Written by Yilin Wang, survey conducted by Yilin Wang, popularization articles written by Fanghui He
　As we formed our project in the inspiration of cancer threrapy, we felt that further investigation on cancer and cancer therapy will help us improve our project. We developed our investigation in three stages.
　In the first stage, we collected some data on the Internet and conducted a survey about public cognition on cancer and cancer therapy.
　In the second stage, we visited some hospitals and deepened our investigation by doing survey focusing on real clinical application of cancer therapies and interviewed Doctor Xianming Li in Shenzhen Renmin hospital in addition.
　In the third stage, we improved our detailed application blueprints according to the results of hospital survey and the aim of solving the existing problems in applying ADCs.
　Additionally, we documented several articles on our We-chat Public Platform, aiming at popularizing the knowledge we gained about cancer and cancer therapy.

About cancer
------Stage 1
　Cancer has been one of the most formidable enemies human faces. 8 million deaths were related to cancer in 2012 worldwide, together with approximately 14 million new cases diagnosed. Although China isn't the most affected country by cancer, according to the world incidence rates, its large population and developing public medical services still lead to considerable mortality. In China, cancer accounted for 23.92% of overall deaths in 2010. And the incidence rate is still growing.

Fig.1 The 10 leading causes of death worldwide in 2011. COPD, chronic obstructive pulmonary disease.
　Generations of scientists devoted their efforts to fighting with cancer.
However, besides continuously developing treatment thechnology, people’s well cognition on the disease is also required for fighting against the disease.
　To observe public cogniton on cancer and cancer therapy,
we documented our survey on our Wechat Public Platform,
an online public platform, and received feedback of an amount of over 600 . The results analyzed are printed below.

Fig. 2 & Fig.3 Our survey conducted among public
　Via: We-chat Public Platform

Fig. 4 　The feedback of public cognition on cancer

Fig.5 The feedback of public cognition on cancer therapy
　As the results shown, when asked about cancer, most people remain knowing "not so much" or "almost nothing at all". And only 19% of the people surveyed know about technologies beside the three main treatment methods(Chemotherapy, Radiotherapy, Surgical Treatment), such as targeted therapy and immunological therapy which may perform more promisingly in future application.
P.S. Therefore, we developed Stage 3, introducing the frontier technologies in cancer treatment field to popularize knowledge of cancer and cancer to the public.

Clinical Application of immunological cancer therapies
------Stage 2
　Aiming at looking into the application landscape of cancer therapies, especially the immunological therapies which is related closely to our project, we conduct a survey in two hospitals.
　By conducting the survey, we collected information about the application frequency of different therapies in treating patients in different stages.

There are two pages

Next